브루셀라병 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Brucellosis Vaccines Market is presumed to reach the market size of nearly USD 441.28 Million by 2032 from USD 279.38 Million in 2023 with a CAGR of 5.21% under the study period 2024-2032.

Brucellosis also is known as malta fever, undulant fever, Mediterranean fever, is an infection caused by undercooked meat of infected animals or ingestion of unpasteurized milk or close contact with their secretion. Brucellosis vaccine is meant for cattle, sheep and goats. Currently, there is no vaccine available for humans. Vaccination works by producing an immune response that increases the animal's resistance to the diseases and is important to control, manage and eliminate brucellosis.

MARKET DYNAMICS

Growing livestock production and the threat of animal-borne infectious diseases are driving the growth of the market. With continuous growth and transformation of the livestock sector offer substantial challenges associated with food security and human nutrition. Demand for livestock products is growing influenced by increasing consumption of milk, meat, and eggs. Globally, brucellosis is considered as the most common zoonotic disease, with more than 500,000 cases recorded annually. Growth of the market is backed by a vaccination programme. On the other hand, there are many regions where effective diagnosis or treatment is not available or where programmes for the detection and prevention of the infection in humans and animals are not adequately carried out. Such regions need co-ordination and collaboration between veterinary and health sectors of government to help prevent and control brucellosis.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Brucellosis Vaccines. The growth and trends of Brucellosis Vaccines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Brucellosis Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines)
• Inactivated
• Live Attenuated
• mRNA Aaccines
• Viral Vector Vaccines

By Route of Administration

• Oral
• Parenteral
• Nasal

By Disease Indication

• Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others)
• Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others)
• Cancer Vaccines
• Allergy Vaccines

By Age

• Pediatric
• Adult

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Brucellosis Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Brucellosis Vaccines market include Merck & Co. Inc., Laboratories Tornel, Hester Biosciences Limited, Ceva, CZ Vaccines. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. BRUCELLOSIS VACCINES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Disease Indication
  • 3.7.4 Market Attractiveness Analysis By Age
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines) Historic and Forecast Sales By Regions
• 5.4. Inactivated Historic and Forecast Sales By Regions
• 5.5. Live Attenuated Historic and Forecast Sales By Regions
• 5.6. mRNA Aaccines Historic and Forecast Sales By Regions
• 5.7. Viral Vector Vaccines Historic and Forecast Sales By Regions

6. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data Analysis By Route of Administration
• 6.3. Oral Historic and Forecast Sales By Regions
• 6.4. Parenteral Historic and Forecast Sales By Regions
• 6.5. Nasal Historic and Forecast Sales By Regions

7. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISEASE INDICATION

• 7.1. Overview By Disease Indication
• 7.2. Historical and Forecast Data Analysis By Disease Indication
• 7.3. Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Historic and Forecast Sales By Regions
• 7.4. Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Historic and Forecast Sales By Regions
• 7.5. Cancer Vaccines Historic and Forecast Sales By Regions
• 7.6. Allergy Vaccines Historic and Forecast Sales By Regions

8. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY AGE

• 8.1. Overview By Age
• 8.2. Historical and Forecast Data Analysis By Age
• 8.3. Pediatric Historic and Forecast Sales By Regions
• 8.4. Adult Historic and Forecast Sales By Regions

9. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1. Overview By Distribution Channel
• 9.2. Historical and Forecast Data Analysis By Distribution Channel
• 9.3. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
• 9.4. Government Suppliers Historic and Forecast Sales By Regions
• 9.5. Others Historic and Forecast Sales By Regions

10. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE BRUCELLOSIS VACCINES COMPANIES

• 11.1. Brucellosis Vaccines Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF BRUCELLOSIS VACCINES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Merck & Co. Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Laboratories Tornel
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Hester Biosciences Limited
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. Ceva
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. CZ Vaccines
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies